Actively Recruiting
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
Led by Seoul National University Bundang Hospital · Updated on 2025-05-25
80
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
S
Seoul National University Bundang Hospital
Lead Sponsor
S
SK Chemicals Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.
CONDITIONS
Official Title
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with type 2 diabetes mellitus
- Adults aged 60 years or older
- Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months
You will not qualify if you...
- Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma
- Patients with poorly controlled blood glucose (HbA1c > 10.0%)
- Patients with an MMSE score below 24
- Patients diagnosed with dementia (e.g., Alzheimer's disease)
- Patients with suspected cognitive impairment due to other causes
- Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
- Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
- Patients with severe depression
- Patients with severe infections, recent surgery (perioperative status), or major trauma
- Patients with pituitary or adrenal insufficiency
- Patients with other medical conditions requiring hospitalization
- Patients with a history of alcohol or drug abuse within 1 year prior to screening
- Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
- Patients deemed by the investigator to be otherwise unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Actively Recruiting
Research Team
S
Soo Lim Dr., MD PhD
CONTACT
M
Minji Sohn Dr, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here